GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

After shares of Novo Nordisk (NVO) fell throughout the last year, the more recent drop may be its last. The company, along with its rival Eli Lilly (LLY), will offer its obesity drug for $499 per ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Goodrx Holdings Inc Cl A (GDRX-Q) from The Globe and Mail including charting and trades.

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

The transaction is led by MCR Investors and its Chairman and CEO, Tyler Morse, with financing from Apollo and Goldman Sachs ...

Investing.com - 美银美林重申对GoodRx Holdings Inc. (NASDAQ: GDRX )的中性评级和5.00美元的目标价，该股目前交易价格为5.15美元，此评级是在公司与诺和诺德公司达成新合作后发布的。根据 InvestingPro 分析，该公司保持着93.68%的高毛利率，并且以4.21的流动比率显示出强劲的财务健康状况。

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Goodrx Holdings Inc.（GDRX）一度上涨超过38.87%，有望创2023年7月31日（当天收涨36.89%、盘中一度上涨38.81%）以来最佳单日表现。该公司与诺和诺德合作，在美国医药市场供应后者的药品。诺和诺德宣布，下调Ozempic的价格。